Search
glutethimide (Doriden)
Tradename: Doriden. DEA-controlled substance: class 3.
Dosage: 250-500 mg PO QHS.
Tabs: 200 & 500 mg.
Pharmacokinetics:
1) highly lipid soluble
2) absorption from GI tract is erratic
3) extensively metabolized in the liver
-> 4-OH metabolite is active
4) 2% of dose excreted unchanged into the urine
5) extensive enterohepatic recirculation
6) glutethimide is a potent stimulator of cyt P450
Adverse effects:
1) excitement
2) blurring of vision
3) gastric irritation
4) headache
5) skin rash
6) respiratory depression, circulatory collapse & coma occur with overdose
7) osteomalacia may occur with chronic use
Laboratory:
1) specimen: serum
- glutethimide in serum/plasma
2) methods: GLC, HPLC, GC-MS
3) other labs with Loincs
- glutethimide in specimen
- glutethimide in gastric fluid
- glutethimide in urine
Interactions
drug adverse effects (more general classes)
General
sedative/hypnotic (tranquilizer)
Properties
MISC-INFO: elimination route LIVER
1/2life 5-22 HOURS
therapeutic-range 2-6 UG/ML
toxic-range >5 UG/ML
protein-binding 50%
elimination by hemodialysis -
hemoperfusion +
peritoneal dialysis -
Database Correlations
PUBCHEM correlations
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Clinical Guide to Laboratory Tests, 3rd ed. Teitz ed.,
W.B. Saunders, 1995